Takeda Pharmaceutical’s oral orexin receptor 2 (OX2R)-selective agonist, oveporexton (TAK-861), achieved all primary and secondary endpoints in two registrational Phase III trials for narcolepsy type 1. The drug improved symptoms including excessive daytime sleepiness and muscle weakness, with a manageable safety profile including insomnia and urinary urgency. Takeda plans regulatory filings in the US and other markets within fiscal 2025. This marks the first late-stage success of an OX2R agonist, a novel mechanism that could open a multimillion-dollar market for treating narcolepsy and related sleep disorders.